Reading orientation
Use the same steps for each treatment guide
This guide does not add clinical claims or rank treatments. Read the sourced answers and their limits. Take personal treatment decisions to a qualified clinician.
Before you compare
- Name your question or decision
- Find the sourced answer for it
- Check what the sources support
- Read what is still unknown
- Save questions to take to a clinician
Read each guide for its details
Each guide has its own sourced wording and limitations. This table cannot replace those details.
Open the full comparison guide →| Guide category | How to use this link | Guide |
|---|---|---|
| No active treatment and appearance choices | Read the guide and its sources. Note its limits and save questions. | Explore |
| Prescription topicals | Read the guide and its sources. Note its limits and save questions. | Explore |
| Phototherapy | Read the guide and its sources. Note its limits and save questions. | Explore |
| Pills, injections, and research treatments | Read the guide and its sources. Note its limits and save questions. | Explore |
| Procedures | Read the guide and its sources. Note its limits and save questions. | Explore |
| Complementary approaches | Read the guide and its sources. Note its limits and save questions. | Explore |
For people with vitiligo and their caregivers
What this page helps you do
Compare each realistic choice using the same benefits, risks, daily effort, evidence limits, and alternatives. Do not let a score choose for you.
- Your task
- Compare realistic options using consistent factors and carry the trade-offs into a shared decision.
- The clinician boundary
- Diagnosis, assessment of activity and body sites, prescribing, monitoring, and personalized treatment decisions belong to a qualified clinician.
Put the realistic options side by side
The treatment comparison names common vitiligo paths and distinguishes US labeling, evidence context, practical burden, unknown cost, and cautions without ranking the choices. This table is a conversation aid, not a score or ranking. Start with the rows that match your goal. “Not established here” means SteadySkin does not have enough supported information to fill that cell without guessing.
| Treatment path | What it is | Evidence strength | Typical use case | Commitment required | Cost band | Key cautions |
|---|---|---|---|---|---|---|
| Topical corticosteroids | Prescription skin medicines that calm inflammation. Vitiligo use is usually off-label in the US. | Guideline-backed | A clinician may discuss one for a patch when a skin medicine fits your goal. | Use at home and check in with your care team. The product and plan matter. | Not established here. | Local skin effects and other risks depend on the product, body area, and plan.Ask your care team |
| Topical calcineurin inhibitors | Skin medicines that are not steroids. Examples are Protopic (tacrolimus) and Elidel (pimecrolimus). Vitiligo use is off-label in the US. | Guideline-backed | A clinician may discuss one as another skin-medicine path. The two medicines are not the same. | Use at home and check in with your care team. The product plan matters. | Not established here. | Label warnings and ultraviolet-light precautions need to fit the full treatment plan.Ask your care team |
| Opzelura (ruxolitinib) cream | A cream that blocks a JAK pathway. Its US label includes nonsegmental vitiligo. | FDA label and clinical studies | A prescriber may discuss it when your diagnosis and health needs fit the current label. | Use at home and check in. You may need help from your health plan. | Not established here. | The label has boxed warnings, skin-cancer precautions, and ultraviolet-exposure guidance.Ask your care team |
| Narrowband UVB (NB-UVB) | Clinician-directed ultraviolet light treatment used in a clinic or at home. | Guideline-backed | A clinician may discuss it for some types of vitiligo and some body areas. | Many sessions, simple records, and check-ins with your care team. | Not established here. | Skin and eye precautions, treatment reactions, and the full clinical plan need team guidance.Ask your care team |
| Excimer or other targeted light | A clinician-directed device that aims light at selected patches. | Discussed in guidelines | A clinician may discuss targeted light for more localized patches. | The treatment-setting commitment is not established here. | Not established here. | Targeted light is not interchangeable with every other light option. The device and plan matter.Ask your care team |
| Surgical or cell-based procedures | A procedure from a specialist. It tries to restore color in chosen areas when vitiligo is stable. | Review evidence | A specialist may discuss it for carefully chosen, stable vitiligo when other paths do not meet your goal. | A specialist visit, a procedure, time to heal, and follow-up. | Not established here. | Healing, scarring, uneven or incomplete results, and color mismatch are possible. Results are not guaranteed.Ask your care team |
| No active treatment | A deliberate choice not to pursue active repigmentation now. Supportive care can still continue, and the choice can be revisited. | Named in guidelines | A valid path when active treatment does not match your goals, priorities, or available energy now. | No treatment routine. Agree on what to watch and when to check in. | No treatment cost band applies. Other care costs are not established here. | Vitiligo may still change. Ask what changes should lead to an earlier check-in.Ask your care team |
I have several options. Where do I start?
Start by naming the goal that matters to you, then place two or three realistic options side by side using the same questions. This can make differences and unknowns easier to discuss, but it cannot interpret your medical history, generate a meaningful personal score, or choose a winner. Evidence Evidence Evidence
Why this matters
Using the same structure reduces the chance that one option is described only by possible benefit while another is described mainly by harm. Waiting, camouflage, and supportive care belong in the comparison when they match your goal; they are not lesser choices because they do not seek repigmentation.
Does “FDA approved” mean an option is best?
No. Identify whether the option is approved, off-label, experimental, procedural, cosmetic, supportive care, or no active treatment. Its status and evidence strength are different. Approval does not guarantee a result. Off-label use is not automatically unsupported. Evidence Evidence Evidence Evidence
Why this matters
Ruxolitinib cream has a defined US vitiligo indication. Tacrolimus, pimecrolimus, and topical corticosteroids appear in vitiligo guidelines without a specific US vitiligo indication. Research approaches and products marketed without approval need their own clear labels.
Which study details actually matter to me?
For each option, ask these questions: Evidence Evidence
- Who was in the study?
- Which body areas and vitiligo patterns were included?
- What was the treatment compared with?
- What counted as success?
- How long were people followed?
- How much did results vary?
- What could the study not answer?
Why this matters
Vitiligo studies use different clinical and patient-reported outcomes, and body areas can respond differently. Results for ruxolitinib, a topical-plus-light combination, and another treatment cannot be collapsed into one interchangeable “success rate.”
What should I compare besides possible benefit?
Compare material risks, reasons an option may not fit, follow-up, clinic and home burden, reversibility, access, and cost uncertainty beside possible benefit. Also include what waiting, camouflage, supportive care, or declining the option would mean for your goal. Evidence Evidence Evidence Evidence Evidence Evidence
Why this matters
Product labels, guidelines, and trials contribute different parts of the picture. Time, travel, cost, and access are valid parts of your decision, but they do not prove one treatment is medically better.
What if I cannot find an answer for one of the options?
Treat the answer as missing—not as zero risk, no benefit, or a guessed value. “Not established,” “not found in the reviewed source,” and “not applicable” mean different things. The gap can become a question for your clinician instead of a false sense of certainty. Evidence Evidence
Why this matters
Evidence gaps are common for direct comparisons, long-term outcomes, particular body areas, children, different skin tones, and day-to-day burden. Naming the gap protects you from the false impression that every important question has been answered.
Questions that can change the next decision
- For your clinicianWhat support could still address my goal without treatment?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- For your clinicianIs this unstudied, uncertain, or not yet reviewed?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- For your clinicianDoes this gap justify another source or opinion?Saving keeps this on your device and needs JavaScript, which is off in this browser.
Evidence behind this page
Sources
Each evidence badge opens the source and its limits. The full list stays available here.
- DailyMed, U.S. National Library of MedicineRegulatory / guideline · not independentRelevant relationship disclosed
- Published
- 2026-01-28
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
Why the independence label says this: The National Library of Medicine hosts DailyMed. The product company submits the label to FDA, so it is authoritative for product labeling but not independent efficacy evidence.
What this source supports
It establishes the US atopic-dermatitis indication, boxed warning, local effects, long-term-use precaution, and ultraviolet instructions for this product.
What it does not support
It does not approve tacrolimus for vitiligo, establish vitiligo efficacy, or resolve off-label guideline discussion of supervised combinations.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.
- DailyMed, U.S. National Library of MedicineRegulatory / guideline · not independentRelevant relationship disclosed
- Published
- 2026-04-30
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
Why the independence label says this: The National Library of Medicine hosts DailyMed. The product company submits the label to FDA, so it is authoritative for product labeling but not independent efficacy evidence.
What this source supports
Supports the US atopic-dermatitis indication, boxed warning, application-site effects, long-term-use precaution and instructions to avoid ultraviolet treatment and minimize natural or artificial sunlight.
What it does not support
It does not approve pimecrolimus for vitiligo, establish vitiligo efficacy or resolve off-label guideline discussion of supervised combinations.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.
- U.S. Food and Drug AdministrationRegulatory / guideline · not independentIndependence not established
- Published
- 2025-09-18
- SteadySkin last checked
- 2026-08-06
What this source can and cannot tell you
What this source supports
Supports the defined US nonsegmental-vitiligo indication, limitations of use, boxed warnings, skin-cancer and ultraviolet precautions, and clinical-study labeling.
What it does not support
It does not guarantee benefit, establish suitability beyond the labeled population or authorize adding phototherapy.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.
- British Journal of Dermatology (Thomas KS, et al.)Clinical research · independentIndependent source
- Published
- 2020-12-28
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
What this source supports
Supports a group-level benefit for the exact supervised topical-corticosteroid and home handheld-light combination studied in active limited vitiligo, alongside minority success, reactions and limited maintenance after treatment ended.
What it does not support
It does not create a general home plan, support other product-device combinations or predict an individual result.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.
- JAMA Dermatology (Ju HJ, et al.)Clinical research · not independentIndependence not established
- Published
- 2021-02-17
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
What this source supports
Supports that multiple surgical techniques have been studied for selected stable vitiligo and that reported response and adverse effects vary by method and study.
What it does not support
Much of the evidence is nonrandomized and an author reported industry relationships; the review does not determine stability, eligibility, color match, durability or individual outcome.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.
- Journal of the European Academy of Dermatology and VenereologyRegulatory / guideline · not independentRelevant relationship disclosed
- Published
- 2023-09-25
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
Why the independence label says this: The journal is the publisher. This label refers to extensive author relationships disclosed for the recommendation, not to the journal itself.
What this source supports
It supports current expert-consensus terminology, clinical assessment, disease-activity evaluation, treatment-goal discussion, and shared decision-making.
What it does not support
It is not independent comparative proof. It cannot diagnose a reader from a description or photograph.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.
- British Journal of Dermatology (Eleftheriadou V, et al.)Regulatory / guideline · independentIndependent source
- Published
- 2022-01-01
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
What this source supports
Supports the clinical history and assessment domains, evaluation of associated autoimmune conditions, its recommendation for thyroid function and antithyroid antibody screening, current classification context, treatment-option map, psychosocial assessment, medical photography and the limits of pediatric evidence.
What it does not support
It was designed for UK care and reviewed literature through May 2019; it does not establish a universal testing plan, prescribe an individual plan, or establish current US labeling or coverage.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.
- American Academy of DermatologyPatient education · not independentIndependence not established
- Published
- 2026-04-15
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
What this source supports
Supports current US patient-language context that lighter patches have multiple causes, dermatologists diagnose vitiligo from history and examination, treatment is optional and several broad management paths exist.
What it does not support
The page acknowledges support from Incyte Dermatology, so it does not independently establish drug efficacy or comparative superiority.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.